Harding Thomas C.'s Form 4 filing
Clovis Oncology, Inc. (CLVS) · filed Oct 4, 2022
- Accession no.
- 0000899243-22-032655
- Filed
- Oct 4, 2022
- Trade date
- Oct 1-3, 2022
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $7.74. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Harding Thomas C.CIK 0001834833 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2022 | Common Stock | MOption exerciseAcquired | +15 | –F1 | – | 3,689 | Indirect | |
| Oct 3, 2022 | Common Stock | SSaleDisposed | −6 | $1.29 | −$7.74 | 3,683 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2022 | Common Stock | MOption exerciseDisposed | −15 | $0.00 | $0 | 109 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each Restricted Stock Unit represents the right to receive one share of Common Stock.
Referenced by the price of 1 transaction in Table I.
Remarks
Senior Vice President and Chief Scientific Officer